Program
SHR-4602
A development code. Also written as “SHR-4602 for injection”.
Its studies are led by Jiangsu HengRui Medicine.
Furthest: phase 2, since Jul 18, 20244 company-led studies, 2 open or runningNext primary completion: Apr 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 42 open or running | phase 2since Jul 18, 2024 | Apr 6, 2023 | Apr 2027phase 2 · NCT06704828 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 6, 2023First study: phase 1 study in Advanced Solid TumorFirst studyNCT05819684 · 133 planned · China
- Jul 18, 2024Phase 2 study in HER2-expressing or -Mutated Unresectable or Metastatic Solid TumorsNCT06516926 · 11 enrolled · China
- Aug 15, 2024Phase 1 study in HER2-expressing or HER2-mutated Locally or Metastatic Solid TumorsNCT06560138 · Australia
- Nov 22, 2024Phase 2 study in Advanced Solid TumorsNCT06704828 · 20 planned · China
Ahead
- Apr 2027Primary completion: phase 2 study in Advanced Solid TumorsNCT06704828
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06704828Advanced Solid Tumors · China | 2 | Not yet recruiting | Apr 2027 | 20 |
| NCT06560138HER2-expressing or HER2-mutated Locally or Metastatic Solid Tumors · Australia | 1 | Withdrawn | Dec 14, 2025 | 0 |
| NCT06516926HER2-expressing or -Mutated Unresectable or Metastatic Solid Tumors · China | 2 | Terminated | May 23, 2025 | 11 |
| NCT05819684Advanced Solid Tumor · China | 1 | Recruiting | May 30, 2025 | 133 |
How it is read
Names in the registry
- “SHR-4602”, 3 entries
- “SHR-4602 for injection”, 1 entry
Codes read as this program: SHR4602.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.